SCHEMBL15547883

SCHEMBL15547883

CCN1[C@H](C)CN(c2ccc(C(=O)O)c(Cl)c2)C[C@@H]1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.49
NR4A1 P22736 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
NOTUM Q6P988 3/20 0.39
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
AVPR2 P30518 1/20 0.37
OPRM1 P35372 1/20 0.37
CTSB P07858 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
THRB P10828 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15559780 0.86 MYC (0.46) MYCNR4A1SMN1; SMN2TSHRCASP1
SCHEMBL15546813 0.85 MYC (0.52) MYCNR4A1SMN1; SMN2TSHRCASP1
SCHEMBL15547434 0.80 MYC (0.52) MYCNR4A1SMN1; SMN2TSHRCASP1
SCHEMBL16874956 0.79 MYC (0.49) MYCNR4A1SMN1; SMN2TSHRCASP1
SCHEMBL15548445 0.79 MYC (0.49) MYCNR4A1SMN1; SMN2TSHRCASP1
SCHEMBL15923351 0.72 MYC (0.57) MYCNR4A1SMN1; SMN2TSHRCASP1
SCHEMBL3119554 0.72 IP6K1 (0.61) MYCNR4A1SMN1; SMN2TSHRCASP1
SCHEMBL25261783 0.72 MYC (0.50) MYCNR4A1SMN1; SMN2TSHRCASP1
SCHEMBL15559500 0.72 MYC (0.36) MYCNR4A1MAPTHTTOPRM1
SCHEMBL15923279 0.72 RAB9A (0.56) MYCNR4A1SMN1; SMN2TSHRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875005-B1 N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS INC (CN) 2020-11-11 EP disclosed
US-10676468-B2 N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof IMPACT THERAPEUTICS, INC. (CN) 2020-06-09 US disclosed
US-20150191460-A1 N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2015-07-09 US disclosed
EP-2875005-A1 N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF Impact Therapeutics, Inc. (CN) 2015-05-27 EP disclosed
WO-2014012511-A1 N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS, INC. (CN) 2014-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10676468-B2 N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof SHH, GLI1, SMO MYC 37/4885NR4A1 282/4885SMN1; SMN2 4566/4885
US-20150191460-A1 N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof SHH, GLI1, SMO MYC 37/4885NR4A1 282/4885SMN1; SMN2 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.